

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Government of India)



Bureau of Pharma Public Sector Undertakings of India

B	Balance Sheet As At 31 March, 2020				
Particulars	Notes	As at	As at		
	no.	31 March, 2020	31 March, 2019		
	_	Amount in Rs.	Amount in Rs.		
I Trust funds / corpus					
Contribution of CPSUs	1	7,500,000	7,500,000		
Reserve and Surplus	2	1,940,815,856	1,571,044,492		
Current liabilities					
Trade payables	3 4	684,321,553	944,349,751		
Others liabilities	4	201,002,225	88,044,122		
Total	_	2,833,639,634	2,610,938,365		
II Assets					
Non-current assets					
Fixed assets	5				
(I) Tangible assets		6,700,289	6,656,810		
(II) Intangible assets		917,736	1,529,560		
Current assets					
Inventories	6	991,205,762	1,163,305,882		
Trade receivables	7	1,146,967,375	1,188,203,211		
Cash and cash equivalents	8	631,652,913	173,300,346		
Short-term loans and advances	9	5,247,042	6,367,613		
Other current assets	10	50,948,517	71,574,944		
Total	_	2,833,639,634	2,610,938,365		
	=				

III See Accompanying Notes Forming Part of Financial Statements

Accountants

1 - 25

As per our report of even date For Gupta Raj Kishore and Associates Chartered Accountants

(Firm Registration No.003909C)

Ranjan Kumar

Partner

Membership No.: 507188 52

Place: New Delhi

Date:

15/01/2021

For Bureau of Pharma Public Sector Undertakings of India

General Manager (F & A)

RAVIKANT TIWARI GM (Finance & Admn.) SACHIN SINGH, IRS Chief Executive Officer

CEO & Secretary General

Pradhan Mantri Bhartiya Janaushadhi Pariyojana



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (Set up under the Department of Pharmaceuticals, Government of India)



Bureau of Pharma Public Sector Undertakings of India Statement Of Profit And Loss For The Year Ended 31 March 2020

	Particulars	Notes	No	Year ended 31 March, 2020	Year ended 31 March, 2019
			-	Amount in Rs.	Amount in Rs.
	Revenue from operations		11	2,771,003,935	2,077,274,745
	Other income		12	9,145,299	18,295,981
I	Total revenue		_	2,780,149,235	2,095,570,726
	Expenses:				
	Cost of goods purchased		13	2,029,719,788	1,963,262,958
	Change in inventories (finished goods)		14	172,100,121	(407,670,833)
	Employee benefit expenses		15	47,485,644	45,662,657
	Finance cost		16	83,448	35,415
	Depreciation and amortization expense		5	2,150,535	2,595,959
	Other expenses		17	504,497,219	545,474,280
II	Total expenses		_	2,756,036,754	2,149,360,437
III	Profit /(Loss) before tax (I-II)	,		24,112,481	(53,789,710)
IV	Current Tax			9,441,118	-
V	Profit /(Loss) Carried forward to BS (III	-IV)		14,671,363	(53,789,710)

See Accompanying Notes Forming Part 1 - 25 of Financial Statements

As per our report of even date For Gupta Raj Kishore and Associates Chartered Accountants

(Firm Registration Nov. 003909C)

Ranjan Kuma Accountants Partner Membership No.: 307188

Place: New Delhi

For Bureau of Pharma Public Sector Undertakings of India

General Manager (F & A)

RAVIKANT TIWARI GM (Finance & Admn.)

SACHIN SINGH, IRS Chief Executive Officer

Pradhan Mantri Bhartiya Janaushadhi Pariyo

CEO & Secretary General